Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | EMN20: KRd versus Rd in non-frail, transplant-ineligible patients with NDMM

In this video, Mattia D’Agostino, MD, University of Turin, Turin, Italy, discusses the results of the EMN20 trial (NCT04096066) which is evaluating carfilzomib, lenalidomide and dexamethasone (KRd) versus Rd in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.